Telix Pharmaceuticals Limited (ASX:TLX) develops and commercialises diagnostic and therapeutic radiopharmaceuticals for cancer. H1 2026 marked a shift in its financial profile, with the company reporting a profit after tax while continuing to invest in late-stage clinical programs and Manufacturing infrastructure. Since the half-year result, Pixclara has also received US approval and entered commercial use, while Zircaix remains subject to further regulatory work.

Revenue Increases to US$477 Million

Group Revenue increased 22% to US$477 million in H1 2026 from US$390 million in the prior corresponding period.

Gross profit reached US$260 million, while the group gross Margin increased to 55%.

Operating profit was US$46 million, compared with US$10 million in H1 2025.

The result reflects continued expansion of Telix’s commercial imaging portfolio alongside higher Investment in research, manufacturing and distribution.

Telix Reports US$38 Million Profit

Profit after tax reached US$38 million, compared with a US$2 million loss a year earlier.

Profit before tax was US$29 million, while the company recorded an income tax benefit of US$9 million.

The result included US$40 million of other income from Telix’s collaboration with Regeneron.

This amount was not product revenue and should therefore be considered separately when assessing recurring operating performance.

Adjusted EBITDA Reaches US$52 Million

Adjusted EBITDA increased to US$52 million from US$21 million in H1 2025.

The increase reflected growth in commercial operations together with the US$40 million collaboration payment.

Telix therefore remains in a transition phase where product sales are supporting a larger proportion of investment, but research, manufacturing and financing costs continue to affect group earnings.

Precision Medicine Remains the Main Earnings Contributor

Precision Medicine revenue increased 27% year on year.

The segment reported a gross margin of 65% and adjusted EBITDA of US$132 million, up 26%.

Telix’s commercial prostate imaging portfolio includes Illuccix and Gozellix.

Illuccix was commercially available in 22 countries at the half-year result, while Gozellix had received US approval.

Illuccix Expansion Continues

Telix continued expanding Illuccix into additional international markets during H1 2026.

The product’s Chinese New Drug Application was accepted for review, while enrolment in the Japanese Phase 3 registrational study was completed.

These regulatory programs could extend the geographic reach of the prostate imaging portfolio, although commercial timing remains dependent on individual market approvals and reimbursement arrangements.

Pixclara Receives FDA Approval

Pixclara, Telix’s brain-cancer imaging product, received FDA approval on September 14, 2026.

The product is indicated for PET imaging to help differentiate recurrent or progressive glioma from treatment-related change in adults and paediatric patients.

This changes the regulatory position described at the August result, when Pixclara was still awaiting an FDA decision.

US Commercial Availability Begins

Telix announced on October 6, 2026 that the first US patients had been dosed with Pixclara.

The first administrations marked the beginning of US commercial availability.

Pixclara therefore becomes another approved Precision Medicine product alongside Telix’s prostate imaging portfolio.

Future contribution will depend on clinician adoption, reimbursement, distribution and manufacturing scale.

Zircaix Remains Awaiting Resubmission

Zircaix remains an investigational kidney-cancer imaging product in the United States.

Telix received a corrected Complete Response Letter and was granted an extension of the deadline for resubmitting its Biologics License Application.

At the H1 result, the company said final chemistry, manufacturing and controls documentation was nearing completion.

No later official announcement reviewed confirms that the resubmission had been filed by October 8, 2026.

Research Spending Rises to US$124 Million

Research and development expenditure increased to US$124 million from US$82 million.

Of this amount, US$68 million was directed toward the therapeutics pipeline.

Telix expects full-year R&D expenditure of between US$230 million and US$270 million.

The investment includes late-stage programs across prostate cancer, renal cancer and brain cancer.

LUTEON Phase 3 Trial Begins Dosing

The first patient was dosed in the Phase 3 LUTEON trial of TLX250-Tx in July 2026.

The study is evaluating the lutetium-177 therapy in patients with relapsed or recurrent clear cell renal cell carcinoma.

Clinical development remains subject to enrolment, safety, efficacy and subsequent regulatory review, meaning the program remains separate from Telix’s approved imaging portfolio.

ProstACT Global Moves Forward

Telix also progressed the ProstACT Global Phase 3 program for TLX591-Tx in metastatic castration-resistant prostate cancer.

The FDA confirmed that Part 1 safety data were sufficient to allow progression of Part 2 in the United States.

Telix and the regulator also aligned on the Part 2 clinical protocol and statistical framework.

The study continues recruiting across multiple jurisdictions.

Manufacturing Business Remains Loss-Making

Telix Manufacturing Solutions reported total segment revenue of US$146 million.

This included US$89 million of third-party product sales and service fees and US$58 million of internal revenue.

The segment recorded an adjusted EBITDA loss of US$23 million and an operating loss of US$33 million.

The losses partly reflect investment in supply-chain and logistics capacity for future therapeutics demand.

Manufacturing Capacity Continues to Expand

TMS includes radiopharmacy and production operations across the United States, Australia, Belgium and Japan.

During H1 2026, Telix opened its North Melbourne Facility and completed a first GMP production run of a lutetium-based therapeutic candidate at its Seneffe site.

These facilities increase production capability but also add costs before utilisation reaches planned levels.

Convertible Debt Extends Funding Capacity

Telix refinanced its Convertible Bond structure by issuing US$600 million of new convertible notes due in 2031.

The notes carry a 1.50% annual coupon.

Finance costs in H1 2026 were US$19 million, largely associated with refinancing activity.

Telix ended June with US$252 million of cash.

Equity Facility Adds Another Funding Option

In August 2026, Telix established an at-the-market facility for its Nasdaq-listed American Depositary Shares.

The company controls whether the facility is used, the number of securities issued and the minimum sale price.

If utilised, new Equity issuance would increase available Capital but also increase the number of shares outstanding.

FY26 Revenue Guidance Is Maintained

Telix expects FY26 revenue to be toward the upper end of its US$950 million to US$970 million guidance range.

Revenue plus other income is expected to exceed US$1 billion, including the US$40 million collaboration payment.

Second-half performance will therefore depend on continued Precision Medicine sales growth together with contributions from recently approved products.

Key Risks and Areas to Watch

Regulatory outcomes remain important because Zircaix has not yet completed the US approval process and therapeutic programs remain in clinical development.

Manufacturing losses and rising R&D spending also reduce the amount of commercial earnings retained by the group.

Other factors include financing costs, possible equity issuance, reimbursement and isotope supply.

Pixclara uptake, Zircaix resubmission, LUTEON recruitment and Precision Medicine margins will remain key indicators.